UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February, 2020
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc
(the 'Company')
Transfer of Treasury Shares
On 10 February 2020, the Company
transferred 25,800,000 ordinary shares of 25 pence each
("Ordinary
Shares") that were held by the
Company in treasury ("Treasury
Shares") to JPMorgan Chase
Bank, N.A. the depositary of the Company's American depositary
receipts ("ADR") programme, to procure the issuance and transfer
of 12,900,000 ADRs of the Company to the GlaxoSmithKline (US) Trust
(the "Trust") to be used to satisfy awards granted under the
Company's Deferred Annual Bonus Plan, Performance Share Plan and
Share Value Plan. The consideration received from the trustee
of $43.95 per ADR, representing $21.975 per Ordinary Share, was
funded by a contribution to the Trust from GlaxoSmithKline
LLC.
Following the transfer, the Company's issued share capital
consisted of 5,384,119,172 Ordinary Shares, of which
367,705,950 were held as Treasury Shares.
Therefore, the total number of voting rights in the Company is
5,016,413,222. This figure may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the Company under the Financial Conduct Authority's
Disclosure Guidance and Transparency Rules.
V A Whyte
Company Secretary
11 February 2020
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: 11
February, 2020
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|